Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Jazz Pharmaceuticals

Stocks To Watch: Jazz Pharmaceuticals Sees Relative Strength Rating Rise To 82

Jazz Pharmaceuticals sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points

On St. Patrick's Day, PDD Holdings and Aon lead five stocks near buy points that are at least a "little Irish."

Investors Business Daily

Jazz Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark

Jazz Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Jazz Pharmaceuticals Trying To Close In On Key Technical Measure

A Relative Strength Rating upgrade for Jazz Pharmaceuticals shows improving technical performance. Will it continue?

Investors Business Daily

Jazz Pharmaceuticals Shows Improved Relative Strength; Still Shy Of Benchmark

A Relative Strength Rating upgrade for Jazz Pharmaceuticals shows improving technical performance. Will it continue?

Investors Business Daily

CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements

The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and communication. That's according to data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, revealed by Jazz Pharmaceuticals plc (NASDAQ: JAZZ).…

Benzinga

Cannabis medications could be eligible for FDA approval under proposed DEA rules

For the first time, cannabis plant would drastically shift federal legal status from narcotic to regulated medication

The Guardian - US

Read news from The Economist, FT, and more,
with one subscription

Scientists to investigate whether CBD can treat psychosis

CBD is currently only prescribed on the NHS for a few conditions

The Independent UK

Oxford study to trial cannabis-based medicine as treatment for psychosis

CBD is currently only prescribed for a small number of conditions such as rare, severe epilepsy

The Guardian - UK

Use of cannabis chemical as psychosis treatment being investigated

CBD is currently only prescribed by the NHS for a few conditions such as epilepsy

Wales Online

3 Biotech Stocks to Help Boost Your Portfolio in January

Increased government initiatives and the rising adoption of biotechnology in healthcare and agriculture are likely to enhance the growth of the biotech industry. Hence, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal additions to your portfolio as they look well-positioned to capitalize…

StockNews.com

Dow Jones Dives On This; Tesla Stock Erases Years Of Gains; These Cathie Wood Buys Plunge

The Dow Jones plunged as recession fears rose. Tesla stock suffered a shocking fall. Some Cathie Wood buys got battered. Apple stock dived.

Investors Business Daily

Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance.

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents with e

Investors Business Daily

IBD 50 Stocks To Watch: This Pharma Stock Rides Health Care Wave

Jazz Pharmaceuticals stands out in the IBD 50 as it rides the wave of the health care sector on concerns of a looming recession.

Benzinga

Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint

Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with multiple sclerosis (MS).

Benzinga

4 Analysts Have This to Say About Jazz Pharmaceuticals

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating

Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level.

Benzinga

What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

Benzinga

Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022.

Benzinga

Jazz Pharmaceuticals: Q1 Earnings Insights

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:05 PM. Here's what investors need to know about the announcement.

Investors Business Daily

Dow Jones Dives; Tesla Stock Craters After Elon Musk Buys Twitter; Microsoft Earnings Beat

The Dow Jones sunk lower. Tesla stock made a bearish move after CEO Elon Musk made a deal to buy Twitter. Microsoft earnings beat.

Benzinga

Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NASDAQ:HOWL) WTX-613. WTX-613 is a differentiated, conditionally-activated interferon-alpha (IFNα) INDUKINE molecule. "We believe WTX-613 has the potential to minimize the toxicity associated with systemic IFNα therapy, preferentially delivering IFNα to tumors, and thereby expanding its clinical utility in treating…

Benzinga

Expert Ratings For Jazz Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.